ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
NICE Approves MabThera(R) (Rituximab) As Maintenance Therapy For Patients With Follicular Non-Hodgkin Lymphoma
The National Institute for Health
and Clinical Excellence (NICE) issued final guidance recommending the use of
MabThera(R) (rituximab), as a maintenance therapy for patients with relapsed/refractory
follicular non-Hodgkin lymphoma (NHL) responding to induction therapy with
chemotherapy with or without rituximab. 1 This is an important breakthrough as it
represents a new treatment approach that can allow patients with this potentially fatal
disease to manage it as a chronic condition and live for an average of over four years
before the disease returns.
Maintenance treatment with rituximab is a new approach to managing NHL, which allows
patients who have responded to initial treatment to receive maintenance therapy every three
months for up to two years. Data have shown that when treated with rituximab
maintenance therapy, patients' risk of death was reduced by 48%. In addition, their
average time of living disease-free was significantly extended to over four years (51.5
months) compared to just 14.9 months when left untreated with maintenance during this
remission period (p
Nisa a aprobat MabThera (R) (rituximab), ca terapie de întreþinere pentru pacienþii cu folicular non-Hodgkin cu limfom - NICE Approves MabThera(R) (Rituximab) As Maintenance Therapy For Patients With Follicular Non-Hodgkin Lymphoma - articole medicale engleza - startsanatate